Log in Subscribe

Report: KY Medicaid spends the most on GLP-1s for obesity per capita of any state

Posted 12/23/24

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the …

This item is available in full to subscribers.

Please log in to continue

Log in